The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...

Health Secretary Robert F. Kennedy Jr. has expressed deep skepticism regarding mRNA vaccines, despite real-world evidence ...

In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential ...

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

The Global Sepsis Diagnostics Market valued at ~$510 million (2021) is set to witness a healthy growth rate of 9% in the next 5 years. Development of rapid diagnostic tests/point-of-care techniques, ...

Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company ...

Debio 1453 is a potent inhibitor of the essential fatty acid synthesis enzyme FabI found in N. gonorrhoeae and a few other bacterial species. It was shown to rapidly trigger bactericidal activity in ...

May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the ...

Vaxart, Inc. announced that it has obtained approval from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to begin dosing ...